BOSTON, Jan. 6 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has received a significant purchase order for the Mammo View(TM) line of surgical endoscopy instruments from the Cleveland Clinic in Cleveland, OH. The Cleveland Clinic currently operates nine community hospitals and three affiliate hospitals which are accredited by the Joint Commission on Accreditation of Healthcare Organization (JCAHO).
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit, multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has become one of the largest and most respected hospitals in the country. Cleveland Clinic facilities can be found throughout Northeast Ohio, as well as, around the country and world
"We are pleased to have the Cleveland Clinic as a client of Solos Endoscopy. We believe the purchase order from a client of this caliber once again validates our surgical products as some of the best on the market. As the Company looks toward the New Year, we will continue to grow our client base and implement strategies to maximize our shareholders value," stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.